Key result
Ischemia modified albumin (IMA) demonstrated high diagnostic accuracy for acute coronary syndrome with an area under the ROC curve of 0.95, and achieved 100% sensitivity when combined with ECG and cTnT.
Why the study?
Does ischemia modified albumin (IMA) improve the diagnostic accuracy for acute coronary syndrome (ACS) in patients presenting with acute chest pain?
Cross-Sectional (n=84)
No
Does ischemia modified albumin (IMA) improve the diagnostic accuracy for acute coronary syndrome (ACS) in patients presenting with acute chest pain?
Effect estimate: AUC 0.95 (95% CI 0.879-0.986)
p-value: p=<0.0001
Ischemia modified albumin (IMA) is a highly sensitive biomarker that, when combined with ECG and cTnT, achieves 100% sensitivity and negative predictive value for diagnosing ACS in patients presenting within 6 hours of chest pain onset.
The aim of this study was to evaluate the diagnostic accuracy of ischemia modified albumin (IMA) alone, or in combination with cardiac troponin T (cTnT) and electrocardiogram (ECG) findings for diagnosis of acute coronary syndrome (ACS). The study included patients with acute chest pain suggestive on ACS, recruited within 6 hours from onset. Patients were classified in ACS group and non-ischemic chest pain group (NICP). Of 84 patients, 49 were diagnosed with ACS and 35 with NICP. IMA was significantly higher in ACS group (p<0.0001). The area under receiver operating curve for IMA in ACS diagnosis was 0.95 (p<0.0001). Sensitivity and specificity of IMA for ACS diagnosis were 89.8% and 91.4%, respectively. IMA significantly (p<0.05) improved the sensitivity of ECG and cTnT, alone, and in combination. Sensitivity and negative predictive value of combination of IMA, ECG and cTnT for diagnosis of ACS were 100%. IMA is useful for diagnosis of ACS, in combination with ECG and cTnT.
No takes yet. Share an insight, caveat, or question.
Dragojević et al. (2013) conducted a cross-sectional in Acute coronary syndrome (n=84). Ischemia modified albumin (IMA) vs. Non-ischemic chest pain was evaluated on Area under receiver operating curve (AUC) for IMA in ACS diagnosis (AUC 0.95, 95% CI 0.879-0.986, p=<0.0001). Ischemia modified albumin (IMA) demonstrated high diagnostic accuracy for acute coronary syndrome with an area under the ROC curve of 0.95, and achieved 100% sensitivity when combined with ECG and cTnT.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: